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Abstract. Pandemic SARS-CoV-2 (COVID-19) is a severe problem in the world today. The 
SARS-CoV-2 virus contains protease and glycoprotein spike, which was used infection and 
development. The RBD (Receptor Binding Domain) of the glycoprotein Spike (RBD-S) can 
bind to the ACE2 receptor (Angiotensin Converting Enzyme-2) on the Domain protease (PD) 
(PD-ACE2) of the host cell causing virus infection. This study aimed to evaluate the potential 
of bioactive peptides from tilapia viscera hydrolysate as an antiviral peptide to attempt a 
simulated docking with four protein target virus COVID 19. The research was conducted by 
molecular docking using the PyRx software. Selected protein targets were SARS-CoV-2 
protease (GDP ID: 6LU7), SPIKE COVID 19 (PDB ID: 6LVN), ACE2 (GDP ID: 6VW1), and 
deubiquitinase inhibitors block the SARS virus replication (PDB ID: 3E9S).  The formed 
binding affinity was represented as a docking score. The results showed that both the Asp-Trp 
and Val-Tyr peptides were potential as SARS-CoV-2 antiviral, with an affinity strength equal 
to chloroquine and favipiravir. The Asp-Trp and Val-Tyr peptides could bind to all four 
receptor proteins target on the active side. Therefore, it potentially inhibits the virus sticking to 
proteins target that results in inhibition of virus replication. Generally, the Asp-Trp and Val-
Tyr peptides of tilapia viscera hydrolysate are potential as an alternative antiviral peptide to 
medicate the infections and replication of COVID-19. 
1. Introduction 
Aquaculture waste such as viscera contain highly protein and unsaturated fatty acids [1]. fish viscera 
can be utilized as a raw material for hydrolysate proteins [2]. It can minimize environmental and 
health issue and reduce the economic impact [3]. One of the efforts to utilize fish waste is using 
hydrolysis technology. Hydrolysis technology breaks down complex bonds into simple bonds in the 
form of bioactive peptides using enzymes, acids, and bases [4]. Bioactive peptides are specific protein 
that possess a health benefit. Proteins in the whole form have weak bioactivity, whereas hydrolyzed 
proteins will increase biological activity because it has been separated from the complex bonds [5]. 
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Bioactive peptides have potential effects as antihypertensive, antioxidants [6], opioid antagonists, 
antibacterial [7], antithrombotic, and immunomodulatory [8]. Peptides extracted from food proteins 
are able to maintain blood pressure, weight balance [9], inhibit the specific endopeptidase activity of 
Prolin, boost the immune system, inhibit blood platelet aggregation, inhibit HIV proteinases and 
oxidation processes, possess antibacterial and antimicrobial activity, ion binding and transport 
minerals and improve nutritional food values [10, 11]. Previous research has shown the numbers and 
diversities of amino acid profiles of tilapia viscera hydrolysate [12, 13], which potentially to be 
developed as a bioactive peptide-based pharmaceutical agent candidate. 
The new Coronavirus, SARS-CoV-2 or COVID 19, became a worldwide outbreak, spreading 
across the continent of Asia, Europe, the Middle East, Africa, and America covering more than 100 
countries. The pandemic of the SARS-CoV-2 virus attracts rapid challenges in finding drugs candidate 
that correspond to the molecular characteristics of the SARS-CoV-2 virus. Researchers have found 
characteristics of the glycoprotein spike structure, which plays an essential role in the SARS-CoV-2 
viral infection [14, 15, 16]. The glycoprotein of SARS-CoV-2 shows a slight difference in the primary 
structure compared to the beta coronavirus, SARS-CoV (due to mutation) so it needs new antiviral 
drugs candidate [17]. 
The Spike of glycoprotein SARS-CoV-2 contains Domain Binding receptors (RBD) that drive the 
virus towards the protein receptors target, and leads to the connection of the trimeric spike proteins to 
S1 and S2, facilitating membrane fusion and virus infections through endocytosis [18]. The 
angiotensin-converting-enzyme 2 (ACE2) is a receptor that is targeted to the glycoprotein spike 
SARS-CoV-2 [19] [20]. Therefore, RBD and glycoprotein spikes are targeted protein receptors to 
inhibit SARS-CoV-2 virus infection (COVID 19). It is noted that many compounds have been traced 
to RBD Spike glycoprotein [21] or with molecular docking model as screening for candidate drugs. 
However, the results show limited candidates to be prospective medications due to threats of adverse 
effects [22, 23, 24]. 
Despite the glycoprotein spike, ACE2 is another candidate that is suitable for drug targets to 
prevent virus infections. Drugs candidate address the spike binding site to bind the spike-RBD 
glycoprotein [18] [25]. The binding site of the Ligan-ACE2 is recognized as a domain protease (PD), 
which plays a role in the trimeric Spike glycoprotein structure as an essential step in virus infections 
[26, 27]. Therefore, the inhibitory effect of some compounds against these receptors suggests 
protecting the virus identifications. 
Protease inhibitors are developed as drug candidates to cease the life cycle of viruses [28]. Beta 
coronavirus uses proteases to break the structural proteins during the formation of viruses in the host 
cell. Protease inhibitors have been developed to prevent spreading viruses such as HIV-AIDS, MERS, 
and SARS [29]. Many drug candidates have also been screened with promising results to treat SARS-
CoV-2 as a drug repurposing, such as lopinavir (the drug HIV-AIDS) [24, 30]. Studies on finding the 
best protease inhibitors to address the SARS-CoV-2 infections were getting increase by using a in 
silico model with a sophisticated crystal structure of domain-inhibitor proteases [31, 32]. This 
approach needs further examine to find best candidates for an antiviral agent that is more precise, 
effective, and has minimal side effects. 
To inhibit the rate of Covid-19 pandemic, the Government of the Republic of Indonesia took the 
policy to use the drug Chloroquine and Favipiravir. The aim of this research was to evaluate the 
potential of bioactive peptides from tilapia viscera hydrolysate as an antiviral peptide to attempt a 
simulated docking with four protein target virus COVID 19, namely SARS-CoV-2 protease (GDP ID: 
6LU7), SPIKE SARS-CoV-2 (GDP ID: 6LVN), RBD-ACE2 complex (GDP ID: 6VW1), and 
deubiquitinase inhibitors blocks of SARS virus replication (GDP ID: 3E9S) compared with 





International Conference on Fisheries and Marine












2. Materials and method 
Tilapia viscera was obtained from PT Aquafarm Nusantara, Semarang Industrial Estate, Indonesia. 
Viscera cleaned with water, and a defatting process was carried out. Furthermore, the hydrolysis 
process was carried out using the alcalase enzyme (Sigma-Aldrich No. 126741) [12].  
Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS) (Thermo Scientific 
Dionex Ultimate 3000) equiped RSLCnano with Microflow meter was used to characterize Tilapia 
viscera hydrolysate. LC-HRMS analysis was conducted using Model LC-HRMS manufacturer. 
Chromatography separation is carried out using the analytical Column Hypersil GOLD aQ 50 × 1 mm 
× 1.9 μ particle size. Two solvents are prepared, 0.1% formic acid in water (A) and 0.1% formic acid 
in acetonitrile (B). Analytical Flow rate 40 ml/min for 30 minutes, column temperature 30 
o
C. HRMS 
Analysis uses Thermo Scientific Q Exactive (Full scan at 70,000 resolution, data-dependent MS2 at 
17,500 resolution, run time 30 minutes). Chromatogram data obtained processed by processing data 
software: Compound discoverer with mzCloud MS/MS library. The second stage is to predict the 
biological activity of hydrolysate compounds using PASS online by including canonical SMILE 
The study of molecular docking was selected as a tool for the screening affinity binding of the 
bioactive peptides contained in the tilapia viscera hydrolysate. The four target proteins of SARS-CoV-
2, namely the SARS-CoV-2 protease (GDP ID: 6LU7), SPIKE COVID 19 (GDP ID: 6LVN), ACE2 
(GDP ID: 6VW1), and deubiquitinase inhibitors blocks of SARS virus replication (GDP ID: 3E9S). 
All simulated computing was performed on the Windows 10 operating system, the Intel Core i5-8th 
Gen as a processor with 4 GB of RAM. Molecular docking studies include activity predictions with 
online PASSES, docking simulations, RMSD calculations, and visualization interactions between 
proteins and peptides performed using PyRx and Biovia Discovery Studio Visualizer 2019. The 
molecular docking results describe the affinity indicated by the docking score and the binding 
interaction of each compound on the four target proteins. Compounds are analyzed for the drug-
likeness Lipinski and toxicity prediction using swissADME and Pro-Tox II. 
 
3. Results and discussion 
3.1 Results 
The results of LC-HRMS analysis, seven peptides were found in the tilapia viscera hydrolysate (Table 
1). 
 
Table 1. Bioactive peptides from the tilapia viscera hydrolysate 
No Bioactive Peptides Chemical structure 
1 Gly-Leu (GL) 
CID 92843 
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Table 2 showed the potential of the seven different peptides detected from tilapia viscera 
hydrolysate as an antiviral, compared with chloroquine and favipiravir. 
 






























Pa Pi Pa Pi Pa Pi Pa Pi Pa Pi Pa Pi Pa Pi Pa Pi 
Asp-Trp 
(7020001) 
0,68 0,00 0,36 0,05 0,35 0,07 0,27 0,05 0,25 0,03 0,27 0,07 








0,39 0,06 0,34 0,06 0,49 0,03 
    
0,24 0,05 0,45 0,01 0,54 0,01 
    
Lys-Pro 
(171204) 
0,35 0,08 0,30 0,09 0,62 0,01 
    
0,23 0,06 0,48 0,00 0,55 0,01 





0,85 0,00 0,55 0,00 0,56 0,02 0,31 0,02 0,21 0,13 0,38 0,01 0,44 0,06 0,27 0,05 
Leu-Leu 
(76807) 
0,89 0,00 0,59 0,00 0,51 0,02 0,34 0,01 0,23 0,06 0,37 0,01 0,42 0,08 0,27 0,05 
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0,82 0,00 0,37 0,04 0,43 0,04 0,33 0,01 0,21 0,11 0,31 0,03 0,31 0,23 0,29 0,04 
Chloroquine 
(2719)                                 
Favipiravir 
(492405) 
0,34 0,09 0,27 0,11 0,66 0,01 0,25 0,08 
            
0,45 0,01 
In order to knowing the potency of  seven peptides from tilapia-viscera hydrolysate against four 
receptor targets, namely: protease SARS-CoV-2 (GDP ID: 6LU7), SPIKE COVID 19 (GDP ID: 
6LVN), RBD-ACE2 (GDP ID: 6VW1), and deubiquitinase inhibitors block the SARS virus 
replication (PDB ID: 3E9S) the molecular docking was conducted and compared with chloroquine and 
Favipiravir as a comparative control. The docking results provide a variation of the D-G binding 
energy (gibbs energy) represented by the docking score between the receptors (Figure 1). 
 
  
Viral Protease (6LU7) Spike Covid 19 (6lvn) 
  
RBD-ACE 2 Complex (6VW1) 
Deubiquitinase inhibitors blocks SARS virus 
replication (3E9S) 
 
Figure 1. Binding energy between seven bioactive peptides with four receptor targets 
 
Figure 1 showed that the Asp-Trp and Val-Tyr peptides have lower gibbs energy than chloroquine 
and favipiravir. Lower binding affinity energy may represent a more potent inhibitory activity against 
viral infections. The results visualizations of Asp-Trp and Val-Tyr peptides with all four receptors 
showed that the Asp-Trp and Val-Tyr bioactive peptides are able to bind the receptors target on the 
expected side (Figure 2, 3, 4, and 5). 
In addition, we try to distinguish if the Asp-Trp and Val-Tyr peptides can serve as drugs (drug-
likeness) based on Lipinski's rules [33]. The toxicity predictions of the Asp-Trp, Val-Tyr, chloroquine, 
and favipiravir peptides were analyzed using Pro-Tox II [34]. The toxicity power is assessed in LD50 
in the unit of mg/kg body weight. Drug-likeness lipinski analysis and toxicity prediction can be seen in 
Table 3. 
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Figure 2. Binding interaction profile of Asp-Trp and Val-Tyr peptides from tilapia viscera hydrolysate 
compared to chloroquine and favipiravir on protease domain of SARS-CoV-2. 
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Figure 3. Binding interaction profile of Asp-Trp and Val-Tyr peptides from tilapia viscera hydrolysate 
compared to chloroquine and favipiravir on spike SARS-CoV-2 
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Figure 4. Binding interaction of Asp-Trp and Val-Tyr peptides of tilapia viscera hydrolysate 
compared to chloroquine and favipiravir on RBD-ACE2 complex 
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Figure 5. Binding interaction profile of Asp-Trp and Val-Tyr peptides from tilapia viscera hydrolysate 
compared to chloroquine and favipiravir on deubiquitinase inhibitors blocks SARS virus replication 
(3E9S). 
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Molecular Weight < 500 
Dalton (g/mol) 
319.31 280.32 319.87 157.10 
High Lipophilicity 
(expressed as Log P < 4.15) 
-0.54 0.61 3.20 -1.30 
Hydrogen Bond Donors < 5 5 4 1 2 
Hydrogen Bond Acceptors 
< 10 
6 5 2 4 
Molar refractivity 40-130 81.36 74.56 97.41 32.91 
Prediction of LD50 
(mg/kg) /  
Toxicity Class 














Table 2 showed activity prediction analysis using PASS online, seven peptides have the potential for 
antiviral activity compared to control (Chloroquine and Favipiravir). PASS online could be used to 
predict biological activities. The highest Pa values group Probability in Active (Pa) types. The 
predicted compound can be proven as an analog of the registered pharmacological agent. It is a 
compound with a value of Pa > 0.7, possibly having a rather high experimental activity, but the 
compound has the possibility of any known pharmacological agent. Compounds with a range of 0.5 < 
Pa < 0.7, possess moderate activity, but their compounds will be less similar to pharmacological 
agents. The value of Pa < 0.5, it is likely to have lower activity, but the level of likeness to the 
compound with known compounds is low, it indicates a new chemical class structure and has 
biological activity that needs to be examined [35]. 
Chloroquine is a pharmaceutical agent used as an antiplasmodial (antimalaria) [36]. Chloroquine is 
able to suppress TNF-α and IL-6 production in rheumatoid arthritis [37] and is used in autoimmune 
therapies such as lupus [38]. The mechanism of action of chloroquine is penetrating to the cells and 
concentrated in the acidic cytoplasm. Chloroquine increases vesicles pH in macrophages or antigen-
presenting cells, thus acting as immunosuppressants by affecting the immune response to antigen [39] 
[40]. 
In addition to being antimalarial and immunosuppressant, chloroquine and hydroxychloroquine are 
potentially used as antiviral [41]. Chloroquine has an antiviral effect on prevention and therapeutic 
mechanisms [42]. In vitro study showed the inhibition of chloroquine to infectious SARS of Cov-2 
[43]. Chloroquine hinders virus replications, and interacts with angiotensin-converting receptor 
enzyme 2 (ACE2). The interaction of chloroquine with ACE 2 can inhibit the virus bonding with the 
receptors, so the virus cannot adhere to the infected receptors, and so that the infection process can be 
prevented [44]. However, the use of chloroquine clinics needs further research, as it has not been 
successfully proven in clinical trial for infected patients with hereditary diseases [45]. Furthermore, 
Favipiravir is antiviral agent as RNA polymerase inhibitor [46].  It can inhibit the RNA Virus 
synthesis [47]. Favipiravir showed antiviral potency to SARS-CoV2 [48]. It is significantly medicated 
SARS-CoV2 in term of in terms of disease spreading and virus clearance [49]. 
Figure 2 showed a bonding visualization between the Asp-Trp and Val-Tyr peptides with proteases 
of the virus. The docking simulation results in the Asp-Trp, Val-Tyr, and chloroquine peptide bonds in 
the viral protease, not on the active side. The amine group of Favipiravir binds to the active site of 
proteases with hydrogen bonds, namely glutamine (GLN A:183), Treonina (THR A:184), and 
Glutamate (A:160). The bonding distance ranges from 2.83 to 2.89 Å. The SARS-CoV-2 virus has an 
amine group (-NH2) in its structure, as it is a single strand RNA virus [50]. This amine group can be a 
target of antiviral compounds. 
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Figure 3 showed a bonding visualization between the Asp-Trp and Val-Tyr peptides with Spike 
SARS-CoV-2. The docking simulation results in the peptide bonds of Asp-Trp, Val-Tyr, Chloroquine, 
and Favipiravir on the SARS-CoV-2 spike, on the active side using hydrogen bonds. The NH2 cluster 
of Asp-Trp binds to spike SARS-CoV-2, on Aspartate (C:17 and D:17), Glutamate (D:21). At the 
same time, the Asp-Trp carboxylic group binds to spike SARS-CoV-2, on Arginine (D:18). The NH2 
cluster of Val-Tyr binds to spike SARS-CoV-2, on Glutamate (D:21). At the same time, the carboxyl 
Asp-Trp cluster binds to spike SARS-CoV-2, at Aspartate (D:17). The NH2 of Chloroquine binds to 
spike SARS-CoV-2, at Aspartate (D:17). The NH2 cluster of favipiravir binds to spike SARS-CoV-2, 
on Glutamate (D:21). CoVs is a positive-strand RNA virus with a crown-like appearance, as it has a 
glycoprotein spike on the surface [51]. Spike glycoproteins on the virus's surface can guide the virus 
towards ACE2 receptor proteins [52]. The Asp-Trp and Val-Tyr peptides from the extract of the tilapia 
viscera hydrolysate are able to bind to the SARS-CoV-2 spike so it cannot bind to the target protein 
receptors. 
Figure 4 showed binding visualization between Asp-Trp and Val-Tyr peptides with the RBD-ACE2 
complex. The docking simulation results in the position of the peptide bonds of Asp-Trp, Val-Tyr, 
chloroquine, and favipiravir on the RBD-ACE2 complex, located on the active side using hydrogen 
bonds. The NH2 cluster of Asp-Trp binds to the RBD-ACE2 complex, at Aspartate (A:319), 
Phenylalanine (A:356). At the same time, the carboxyl Asp-Trp cluster binds to the RBD-ACE2 
complex, on Alanine (A:317), Aspartate (A:319), and Arginine (A:358). The NH2 cluster of Val-Tyr 
binds the RBD-ACE2 complex, in Threonine (B:908) and Glutamate (B:940). The ester group of the 
Val-Tyr binds to the RBD-ACE2 complex at Arginine (B:1045).  
The amide group of the Val-Tyr binds to the RBD-ACE2 Complex in Threonine (B:908). The 
hydroxyl group of the Val-Tyr binds to the RBD-ACE2 complex on Glutamate (B:911) and Proline 
(B:884). The NH2 cluster of chloroquine binds to the RBD-ACE2 complex on Alanine (B:886). The 
NH2 cluster of favipiravir binds to the RBD-ACE2 complex on Glutamate (B:940). RBD is a primary 
domain peptide in infectious pathogenesis. RBD is the active site of binding for Angiotensin-
Converting Enzyme 2 (ACE2) receptors of humans. ACE2 is an enzyme located on the surface 
(membrane) of organ cells, such as the lungs, arteries, heart, kidneys, and intestines [53]. The SARS-
CoV could infect the host cell through the ACE 2 receptor protein [54]. The SARS-CoV-2 protein 
spike has a strong binding affinity with human ACE2 [55]. The bonds with the ACE2 receptor was 
able to help the SARS-CoV-2 infected a host cell [56]. Therefore, the suspected Asp-Trp and Val-Tyr 
peptides can inhibit binding between the SARS-CoV-2 and the RBD spike. This inhibition allows 
delaying of viruses binding on the ACE2 receptors in the lungs and other tissues. 
Figure 5 showed a binding visualization between the Asp-Trp and Val-Tyr peptides with 
deubiquitinase inhibitors blocks SARS virus replication (3E9S). The docking simulation results in the 
position of Asp-Trp, Val-Tyr, and favipiravir peptide bonds in the 3E9S protein, on the active side 
using hydrogen bonds. The amine group of Asp-Trp binds to protein 3E9S, in Tyrosine (A:265 and 
A:274). The carboxamide cluster of Asp-Trp binds to protein 3E9S on Glutamine (A:270). The Asp-
Trp ester group binds to protein 3E9S in Threonine (A:302). The amine group of the Val-Tyr binds to 
protein 3E9S in Threonine (A:75). The carboxyl cluster of Val-Tyr binds to protein 3E9S on the 
Proline (A:60). Favipiravir's amine group binds with protein 3E9S on Glutamate (A:78) and Leucine 
(A:76). The SARS-CoV has two large polyproteins that have been coded in its genomic sequence, 
namely papain-like protease (PLpro) and the 3-chymotrypsin-like protease (3CLpro). Polyproteins in 
viruses plays important action in the virus maturation and infection [57]. These two polyproteins play 
a pivotal role in virus-mediated RNA replication, such as the SARS-CoV-2 (COVID-19) [58]. Both 
polyproteins are play key role in the virus life cycle and become a target of the SARS-CoV antiviral 
drug design [59]. 
Table 3 showed that Asp-Trp and Val-Tyr bioactive peptides from the tilapia viscera hydrolyzate 
extract meet drug-likeness rules and have LD50 (Prediction) which is safe for consumption. The 
bioactive peptide is a compound that has a health function for the human body. Bioactive peptides 
have unique amino acid structure and composition and have biological functions [60]. Bioactive 
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peptides formed when encrypted peptides become active by acid hydrolysis, chemical alkali, 
proteolytic microorganisms, and enzymatic hydrolysis [61]. In this study, the viscera of tilapia 
hydrolyzed with the enzyme alcalase, and this hydrolysis process made extracts of tilapia viscera 
hydrolyzate contain bioactive peptides and have biological functions. Viscera is a fishery waste that 
could be used to obtain protein hydrolyzate, which is rich in bioactive peptides. Waste from 
agroindustry is a rich source of protein and can be an alternative in obtaining bioactivity compounds, 
especially protein hydrolyzate [62]. 
Previous study showed that a short-chain peptide (less than 30 strands of amino acids) have broad-
spectrum antiviral properties [63]. These short-chain peptides may interact with virus and/or 
glycoprotein receptors through target cells to inhibit the bonding between receptors and viruses that 
can interfere with virus replication [64, 65]. Short-chain peptides can also disrupt the virus casing; 
therefore, it is impeded the virus from entering the target cell [66, 67]. Bioactive peptides are also 
reported to be antiviral in the H1N1 influenza virus, H5N1, and SARS-CoV [68]. Studies of the 
molecular docking peptide bioactive Asp-Trp and Val-Tyr from the tilapia viscera hydrolysate 
demonstrated its ability to bind to the viral receptor proteins' active site play a role in the replication, 
maturity, and inhibition of the SARS-CoV-2 virus (COVID 19) in the target protein. 
Antiviral peptide tilapia hepcidin 1-5 modulate immune-related gene expressions against infectious 
pancreatic necrosis virus (IPNV) [69]. The antiviral peptide polyphemucine, tachyplesin, defensin-like 
isolated from crab and mussel possess antiviral activity [3]. Blood-like waste is also produced antiviral 
peptide [70]. This antiviral peptide potentially becomes an alternative in virus infections that invade 
the respiratory tract [71]. Also, the advantage of the antiviral peptide is synthetically produced [72, 
73]. Therefore, an antiviral agent peptide-based is a promising therapeutic of the SARS-CoV-2 
infection (COVID 19). 
 
4. Conclusion 
The bioactive peptides of Asp-Trp and Val-Tyr had better interaction with the SARS-CoV-2 protease 
(COVID 19) compared with chloroquine and favipiravir in the molecular docking study. In additions, 
bioactive peptides Asp-Trp and Val-Tyr exhibited better interaction with Spike-RBD, a receptor 
protein that directs the virus to attach to the ACE2 (the viral receptor target SARS-CoV-2). Besides, 
the bioactive peptides of Asp-Trp and Val-Tyr can bind to polyproteins instrumental in maturase and 
viral replication. Bioactive peptides of Asp-Trp and Val-Tyr could potentially be an antiviral peptide 
withs targets stopping the infection and replication of the SARS-CoV-2 (COVID 19). 
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